Competition in Biofilms between Cystic Fibrosis Isolates of Pseudomonas aeruginosa Is Shaped by R-Pyocins
暂无分享,去创建一个
[1] A. Oliver,et al. Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients , 2018, The Journal of antimicrobial chemotherapy.
[2] D. Scholl. Phage Tail-Like Bacteriocins. , 2017, Annual review of virology.
[3] E. Nash,et al. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers , 2017, Thorax.
[4] M. P. Mokoena. Lactic Acid Bacteria and Their Bacteriocins: Classification, Biosynthesis and Applications against Uropathogens: A Mini-Review , 2017, Molecules.
[5] Fengan Yu,et al. Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa , 2016, Applied and Environmental Microbiology.
[6] I. Kukavica-Ibrulj,et al. Temperate phages enhance pathogen fitness in chronic lung infection , 2016, The ISME Journal.
[7] J. Kitzman,et al. Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs. , 2015, Cell host & microbe.
[8] K. Foster,et al. Biofilm Formation As a Response to Ecological Competition , 2015, PLoS biology.
[9] M. Brockhurst,et al. Divergent, coexisting Pseudomonas aeruginosa lineages in chronic cystic fibrosis lung infections. , 2015, American journal of respiratory and critical care medicine.
[10] J. Corander,et al. Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection , 2015, Scientific Reports.
[11] G. Walker,et al. Biological Cost of Pyocin Production during the SOS Response in Pseudomonas aeruginosa , 2014, Journal of bacteriology.
[12] R. Rajendran,et al. Activity of Pyocin S2 against Pseudomonas aeruginosa Biofilms , 2011, Antimicrobial Agents and Chemotherapy.
[13] M. Brockhurst,et al. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. , 2011, American journal of respiratory and critical care medicine.
[14] Nazanin Saeidi,et al. A predicted S‐type pyocin shows a bactericidal activity against clinical Pseudomonas aeruginosa isolates through membrane damage , 2010, FEBS letters.
[15] C. van Delden,et al. Lipopolysaccharide as Shield and Receptor for R-Pyocin-Mediated Killing in Pseudomonas aeruginosa , 2010, Journal of bacteriology.
[16] Steven R. Williams,et al. An Engineered R-Type Pyocin Is a Highly Specific and Sensitive Bactericidal Agent for the Food-Borne Pathogen Escherichia coli O157:H7 , 2009, Antimicrobial Agents and Chemotherapy.
[17] M. Cámara,et al. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. , 2009, Current opinion in microbiology.
[18] Steven R. Williams,et al. Retargeting R-Type Pyocins To Generate Novel Bactericidal Protein Complexes , 2008, Applied and Environmental Microbiology.
[19] D. Scholl,et al. Antibacterial Efficacy of R-Type Pyocins towards Pseudomonas aeruginosa in a Murine Peritonitis Model , 2008, Antimicrobial Agents and Chemotherapy.
[20] C. Keel,et al. Biocontrol of Root Diseases by Pseudomonas fluorescens CHA0: Current Concepts and Experimental Approaches , 2007 .
[21] You-Hee Cho,et al. R-type pyocin is required for competitive growth advantage between Pseudomonas aeruginosa strains. , 2007, Journal of microbiology and biotechnology.
[22] Song Jae-Hoon,et al. Profiling Pyocins and Competitive Growth Advantages of Various Pseudomonas aeruginosa Strains , 2005 .
[23] Y. Michel-Briand,et al. The pyocins of Pseudomonas aeruginosa. , 2002, Biochimie.
[24] H. Mori,et al. The R‐type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F‐type is related to lambda phage , 2000, Molecular microbiology.
[25] S. Lory,et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.
[26] S. Lory,et al. Complete genome sequence of Pseudomonas aeruginosa PAO 1 , an opportunistic pathogen , 2000 .
[27] M. Riley,et al. Molecular mechanisms of bacteriocin evolution. , 1998, Annual review of genetics.
[28] F. Ausubel,et al. Common virulence factors for bacterial pathogenicity in plants and animals. , 1995, Science.
[29] David N. Dowling,et al. Molecular ecology of rhizosphere microorganisms : biotechnology and the release of GMOs , 1994 .
[30] M. Kageyama. [Pyocins and their genetic determinants]. , 1985, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[31] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[32] A. Pühler,et al. A Broad Host Range Mobilization System for In Vivo Genetic Engineering: Transposon Mutagenesis in Gram Negative Bacteria , 1983, Bio/Technology.
[33] M. Kobayashi,et al. Characterization of a bacteriophage related to R-type pyocins , 1979, Journal of virology.
[34] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.
[35] F. Egami,et al. STUDIES OF A PYOCIN. III. BIOLOGICAL PROPERTIES OF THE PYOCIN. , 1964, Journal of biochemistry.